A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Alpelisib (Primary) ; Ribociclib (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 13 Jun 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 13 Jun 2019 Planned primary completion date changed from 15 Nov 2019 to 17 Nov 2020.
- 11 Feb 2019 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History